Abstract
For more than 60 years, genetic variation had been recognized as an important determinant of inter-individual variability in drug efficacy and drug safety. Pharmacogenomics, studying the variations of DNA sequence and gene expression related to drug responses, is the whole genome application of pharmacogenetics. The aim of PGt/PGx is to elucidate functionally relevant genomic determinants for drug metabolism, transport and response in order to optimize drug therapy including therapy response prediction, appropriate drug selection and individualization based on the patient's genomic profile. This article describes and surveys the international landscape on recent PGt/PGx applications in clinical practice. A topline list of drugs in personalized medicine is highlighted together with the cutting edge initiatives such as the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
Keywords: Collective innovation, drug efficacy and safety, drug metabolizing enzyme, drug receptor, drug transporter, personalized medicine, pharmacogenetics, pharmacogenomics.
Current Pharmacogenomics and Personalized Medicine
Title:Translating Pharmacogenetics and Pharmacogenomics: The Last 60 Years and the Rise of Collective Innovation as a Force Multiplier for Personalized Medicine
Volume: 12 Issue: 1
Author(s): Yu Cheng, Yi-Jing He, Jie Tang and Hong-Hao Zhou
Affiliation:
Keywords: Collective innovation, drug efficacy and safety, drug metabolizing enzyme, drug receptor, drug transporter, personalized medicine, pharmacogenetics, pharmacogenomics.
Abstract: For more than 60 years, genetic variation had been recognized as an important determinant of inter-individual variability in drug efficacy and drug safety. Pharmacogenomics, studying the variations of DNA sequence and gene expression related to drug responses, is the whole genome application of pharmacogenetics. The aim of PGt/PGx is to elucidate functionally relevant genomic determinants for drug metabolism, transport and response in order to optimize drug therapy including therapy response prediction, appropriate drug selection and individualization based on the patient's genomic profile. This article describes and surveys the international landscape on recent PGt/PGx applications in clinical practice. A topline list of drugs in personalized medicine is highlighted together with the cutting edge initiatives such as the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
Export Options
About this article
Cite this article as:
Cheng Yu, He Yi-Jing, Tang Jie and Zhou Hong-Hao, Translating Pharmacogenetics and Pharmacogenomics: The Last 60 Years and the Rise of Collective Innovation as a Force Multiplier for Personalized Medicine, Current Pharmacogenomics and Personalized Medicine 2014; 12 (1) . https://dx.doi.org/10.2174/1875692111666131223235548
DOI https://dx.doi.org/10.2174/1875692111666131223235548 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
2,4,6-Trichlorophenylhydrazine Schiff Bases as DPPH Radical and Super Oxide Anion Scavengers
Medicinal Chemistry The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Current Nanoscience The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Current Hypertension Reviews Mammalian Antimicrobial Peptides: Promising Therapeutic Targets Against Infection and Chronic Inflammation
Current Topics in Medicinal Chemistry Immune Status 'in Children with Beta Thalassemia' in Correlation 'with Iron Overload': Single Center Egyptian Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Strategies in Drug Discovery of the Calcium-Sensing Receptor Based on Biased Signaling
Current Drug Targets FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer
Current Signal Transduction Therapy Evaluation of Glucose and Lipid Lowering Activity of Arganimide A in Normal and Streptozotocin-Induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Methicillin-Sensitive <i>Staphylococcus aureus</i> Pyogenic Iliopsoas Abscesses: A Case Series from Jodhpur, India
Infectious Disorders - Drug Targets Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease
Current Alzheimer Research Editorial [ The Wide Roles of Cytokines During Evolution Executive Editors: M. de Eguileor and E. Ottaviani ]
Current Pharmaceutical Design Comparative Efficacy and Safety Study of Darbepoetin Alfa <i>versus</i> Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
Current Drug Safety MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry Mast Cells: Target and Source of Neuropeptides
Current Pharmaceutical Design CRF Receptors as a Potential Target in the Development of Novel Pharmacotherapies for Depression
Current Pharmaceutical Design